Skip to main content
TipRanks
Go Ultimate75% OFF

Barclay Phillips Insider Profile

4 Followers

Barclay Phillips, Director at Immunic, holds ― shares in Immunic (Ticker: IMUX), holds 0.00 shares in G1 Therapeutics (Ticker: GTHX), holds 9.56K shares in Novavax (Ticker: NVAX).

Barclay Phillips's Trading History

GTHX
G1 Therapeutics
Nov 16, 2018―Uninformative Buy97.30K$0.00
NVAX
Novavax
Aug 01, 2017SVP, Chief Financial OfficerUninformative Buy1.83K$81.47K
ACORQ
Acorda Therapeutics
―――$4.01K
IMUX
Immunic
―Director――

You May Also Like

Barclay Phillips insider profile FAQ

What is the percentage of profitable transactions made by Barclay Phillips?
The percentage of profitable transactions made by Barclay Phillips is 100%.
What is the average return per transaction made by Barclay Phillips?
The average return per transaction made by Barclay Phillips is 79.20%.
What stocks does Barclay Phillips hold?
Barclay Phillips holds: IMUX, NVAX, GTHX, ACORQ stocks.
What was Barclay Phillips's most profitable transaction?
Barclay Phillips’s most profitable transaction was an Informative Buy of NVAX stock on October 6, 2014. The return on the trade was 189.20%.
What is Barclay Phillips's role in Immunic?
Barclay Phillips's role in Immunic is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.